Proprietary formula from natural origin with immediate clinically proven efficacy

Proprietary formula from natural origin
with immediate clinically proven efficacy
in reducing allergy symptoms without side effects
SniZtop is a unique product which fights any kind
of allergic reaction, except for food allergy.
Its proprietary formula based on natural
active ingredients offers immediate relief
from allergy symptoms (within 30 minutes)
and has an excellent safety profile,
for both adults and children.
SniZtop is free from the undesirable
side effects such as sleepiness and drowsiness
that most anti-allergy drugs cause.
A 2-phase, randomized, double-blind,
placebo-controlled trial is currently being conducted
to further prove the fast action of SniZtop.
First results from phase 1 show a quick onset
of action already noticeable with 1 tablet/day.
Study results will be available in September 2013.
Why SniZtop
A unique product for allergy relief with an excellent safety profile
and supported by a proprietary clinical study.
D E VELOP MENT O F U NI Q U E , I NNO VA TI VE , C LI N I C A LLY PRO V E N PRO DU C T S
INDICATION & COMPOSITION
• Prevention & acute approach of any kind of allergic reaction
(dust, pollen, pet dander…) other than food allergy
• For adults & children
• Active ingredients: standardized proteins from quail eggs which inhibit the release of allergy mediators
(ILK, histamine…)
• Quick onset of action (30 min after product intake)
TECHNICAL
REGULATORY
• Supplied as tablets (bulk or blistered)
• Manufactured in the EU (GMP compliant)
• Food supplement (EU)
• One EFSA-approved claim available if zinc or
selenium are incorporated:
Contributes to a normal function of the immune system
• Targeting EFSA product specific health claim
(Art. 13.5)
CLINICAL STUDIES
• New, on-going, 2-phase, randomized, double-blind, placebo-controlled study.
Objectives:
- Phase 1 (Dec’12-Feb’13): define minimum effective dose
- Phase 2 (May-Sep’13): confirm efficacy on immediate relief from allergy symptoms
Peak Nasal Inspiratory Flow (PNIF) (ml/min)
Mean change from baseline in Peak Nasal Inspiratory Flow (PNIF)
after exposure to a standardized allergenic challenge
in subjects taking 1 or 2 tablets of SniZtop vs placebo (N=11)
120
1 tablet/day
100
2 tablets/day
80
Placebo
60
40
-15
0
15
30
45
60
75
90
105
120
Time after intake (minutes)
Exposure SniZtop or
to allergens placebo
intake
The trademark/brand name and claims herein are used by STRAGEN PHARMA SA for B2B purposes only.
Any other use of this trademark/brand name requires STRAGEN’s prior written agreement.
It is distributor’s responsibility to ensure compliance with applicable local regulations.
STRAGEN PHARMA SA
Chemin du Pré-Fleuri 3 Zone Industrielle 1228 Plan-les-Ouates / Geneva Switzerland
Tel. +41 22 799 19 19 Fax +41 22 799 19 99
[email protected] www.stragenhealth.com
D E VELOP MENT O F U NI Q U E , I NNO VA TI VE , C LI N I C A LLY PRO V E N PRO DU C T S
June 2013
30 minutes after product intake, nasal obstruction decreased with SniZtop
while it increased in subjects taking placebo.